Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis |
| |
| Affiliation: | 1. College of Pharmacy, Chicago State University, 9501 S. King Drive Douglas Hall 206, Chicago, IL 60628, United States;2. Department of Pharmacy, University of Utah Hospitals and Clinics, Salt Lake City, UT, 50 North Medical Drive, Salt Lake City, UT 84103, United States;3. Department of Pharmacy, Northwestern Medicine, Chicago, IL, 676N Saint Clair Street, Arkes Family Pavilion Suite 560, Chicago, IL 60611, United States;4. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 676N Saint Clair Street, Arkes Family Pavilion Suite 1600, Chicago, IL 60611, United States;5. Department of Pharmacy, The University of Kansas Health System, Kansas City, KS, 3901 Rainbow Boulevard, Mailstop 4040, Kansas City, Kansas 66160, United States;6. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, 3400 Civic Center Boulevard, Philadelphia, PA 19104, United States;7. Department of Pharmacy, University of Chicago Medicine, Chicago, IL, 5841 S Maryland Avenue, MC0010, Chicago, IL 60637, United States;1. Department of Pediatrics, Division of Pediatric Pulmonology, Johns Hopkins University, Baltimore, MD, United States of America;2. Department of Pediatrics, Division of General Pediatrics, Johns Hopkins University, Baltimore, MD, United States of America;3. Department of Medicine, Division of Pulmonary & Critical Care Medicine, Johns Hopkins University, Baltimore, MD, United States of America;4. Department of Pediatrics, Pediatric Pulmonary Section, Baylor College of Medicine, Houston, TX, United States of America;1. Imaging Department, Hopital Nord, APHM, Aix Marseille University;2. Aix Marseille Univ, LIIE, Marseille, France;3. Aix Marseille Univ, CERIMED, Marseille, France;4. Service de Pneumologie et équipe de transplantation pulmonaire, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) Adulte, AP-HM Hôpital Nord,13015, Marseille France;5. Aix Marseille Université, Service de radiologie, La Timone Hôpital, 264 rue Saint Pierre, 13005 Marseille;6. Service d''anatomie et cytologie pathologiques, Hôpital Nord, chemin des Bourrely, 13015 Marseille, France;7. U1068- CRCM, Aix Marseille université, 13015 Marseille, France;8. Service de chirurgie thoracique et Transplantation Pulmonaire, hôpital Nord, chemin des Bourrely, 13015 Marseille, France;9. Aix Marseille Univ, APHM, INSERM, IRD, SESSTIM, ISSPAM, Hop Timone, Biostatistics department, BIOSTIC, Marseille, F-13005, France;1. Department of Pediatrics, UNC School of Medicine, University of North Carolina, 450 MacNider Building, CB# 7217 321 S. Columbia Street, Chapel Hill, NC, United States;2. Department of Biostatistics, University of North Carolina, Chapel Hill, NC, United States;3. Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, United States;4. Department of Infection Prevention & Control, New York-Presbyterian Hospital, New York, NY, United States;1. Department of Pediatrics, Washington University, St. Louis, MO, United States;2. Department of Pediatrics, University of Washington, Seattle, WA, United States;3. Seattle Children''s Hospital, Seattle, WA, United States;4. Department of Biostatistics, University of Washington, Seattle, WA, United States;5. Department of Pediatrics, Children''s Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, CO, United States;6. Department of Pediatrics, University of North Carolina, Chapel Hill, NC, United States;1. Microbiomes Microbes and Informatics Group, Organisms and Environment Division, School of Biosciences, Cardiff University, Sir Martin Evans Building, Park Place, Cardiff, UK;2. Department of Paediatric Respiratory Medicine, Noah''s Ark Children''s Hospital for Wales, Cardiff, UK;3. School of Medicine, Cardiff University, UK;4. Department of Paediatric Physiotherapy, Noah''s Ark Children''s Hospital for Wales, Cardiff, UK;5. Molecular Biosciences Division, School of Biosciences, Cardiff University, Sir Martin Evans Building, Park Place, Cardiff, UK;2. Slovak Cystic Fibrosis Association, Slovakia;3. Warsaw Cystic Fibrosis Centre, Dziekanow Lesny Paediatric Hospital, Institute of Mother and Child, Warsaw, Poland;4. Department of Cystic Fibrosis, National Koranyi Institute for Pulmonology, Budapest, Hungary;5. Paediatric Clinic, Paediatric Department, University Hospital Alexandrovska, Medical University Sofia, Sofia, Bulgaria;6. Institute of Hereditary Pathology of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine;7. Latvian Cystic Fibrosis Society, Latvia |
| |
| Abstract: | Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
